# NON-CLINICAL SAFETY OF PTH-IA, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE.

> **NIH NIH N01** · IIT RESEARCH INSTITUTE · 2024 · $115,334

## Abstract

The objective of this study is to determine toxicity and toxicokinetics of PTH-IA
after BID daily subcutaneous administration in 7 day old rats for 6 month
with a 28 days recovery period.

## Key facts

- **NIH application ID:** 11041824
- **Project number:** 271201700016I-P00006-759502000001-1
- **Recipient organization:** IIT RESEARCH INSTITUTE
- **Principal Investigator:** THOMAS HORN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $115,334
- **Award type:** —
- **Project period:** 2020-09-16 → 2024-07-08

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11041824

## Citation

> US National Institutes of Health, RePORTER application 11041824, NON-CLINICAL SAFETY OF PTH-IA, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. (271201700016I-P00006-759502000001-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11041824. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*